HCV drug sales drag down Gilead's 1Q18 earnings

Gilead Sciences Inc. (NASDAQ:GILD) was off $4.16 to $68.40 in early after-hours trading on Tuesday after reporting 1Q18 earnings that missed analyst estimates for revenue and EPS amid a continued decline in HCV drug sales.

The company posted revenue of $5.1 billion and non-GAAP EPS of $1.48 vs. the Street consensus of $5.4 billion and $1.67, respectively. Sales dropped 22% and EPS fell 34% compared with Gilead's 1Q17 results...